In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay.

abstract：BACKGROUND:The role of adjuvant therapy in pancreatic cancer remains controversial. Gemcitabine given systemically seems to be effective; intra-arterial chemotherapy (IAC) has a deep rationale. PATIENTS AND METHODS:The goal was to evaluate the impact of postoperative IAC followed or not by systemic gemcitabine in pati...

journal_title：Cancer chemotherapy and pharmacology

authors： Cantore M,Serio G,Pederzoli P,Mambrini A,Iacono C,Pulica C,Capelli P,Lombardi M,Torri T,Pacetti P,Pagani M,Fiorentini G

更新日期：2006-10-01 00:00:00

abstract：PURPOSE:Brivanib alaninate is a prodrug of brivanib (BMS-540215), a potent oral VEGFR-2 inhibitor and is currently in development for the treatment of hepatocellular and colon carcinomas. In vitro and in vivo studies were conducted to characterize the preclinical pharmacokinetics and disposition of brivanib and brivani...

journal_title：Cancer chemotherapy and pharmacology

authors： Marathe PH,Kamath AV,Zhang Y,D'Arienzo C,Bhide R,Fargnoli J

更新日期：2009-12-01 00:00:00

abstract：PURPOSE:The aims of this dose-escalating phase I study were to determine the maximum tolerable dose (MTD) and recommended dose (RD) of 5-fluorouracil (5-FU), docetaxel, and nedaplatin (UDON) combination therapy for future phase II studies, and to evaluate the safety and efficacy of this regimen in patients with untreat...

journal_title：Cancer chemotherapy and pharmacology

authors： Ueda S,Kawakami H,Nishina S,Sakiyama T,Nonagase Y,Okabe T,Tamura T,Nakagawa K

更新日期：2015-08-01 00:00:00

abstract：PURPOSE:Thymidylate synthase (TS) is one of the target molecules for the antitumor effects of fluoropyrimidine drugs. The cellular thymidylate synthase level is one of the determining factors for the antitumor activity of fluoropyrimidines. TYMS, which encodes TS, has been reported to possess 28-bp tandem repeat sequen...

journal_title：Cancer chemotherapy and pharmacology

authors： Yawata A,Kim SR,Miyajima A,Kubo T,Ishida S,Saito Y,Nakajima Y,Katori N,Matsumoto Y,Fukuoka M,Ohno Y,Ozawa S,Sawada J

更新日期：2005-11-01 00:00:00

abstract：PURPOSE:Our study was designed to evaluate the efficacy and safety of everolimus in patients with pre-treated metastatic gastric and esophagus cancers in a US-based population focusing on biomarker correlation. METHODS:Patients with advanced upper GI adenocarcinomas who progressed after 1-2 prior regimens received eve...

journal_title：Cancer chemotherapy and pharmacology

authors： Wainberg ZA,Soares HP,Patel R,DiCarlo B,Park DJ,Liem A,Wang HJ,Yonemoto L,Martinez D,Laux I,Brennan M,Hecht JR

更新日期：2015-07-01 00:00:00

abstract：:The stability of solutions of the antitumour antimetabolites, vinca alkaloids, podophyllotoxins, interferons, steroids and platinum drugs as well as maytansine, asparaginase, amsacrine, flavone-8-acetic acid, mitoguazone, and N-phosphonoacetyl-L-aspartate (PALA) is reviewed. Much of the published work has been done wi...

journal_title：Cancer chemotherapy and pharmacology

authors： Bosanquet AG

更新日期：1989-01-01 00:00:00

abstract：:Purified human leukocyte interferon produced by recombinant techniques (IFN-alpha A) was tested in vitro with chemotherapeutic drugs, vinblastine (VLB), vincristine (VCR), vindesine (VDS), vinzolidine (VZL), cis-platinum (PLAT), doxorubicin (DOXO), etoposide (VP-16), and melphalan (MEL). The activity of these agents a...

journal_title：Cancer chemotherapy and pharmacology

authors： Aapro MS,Alberts DS,Salmon SE

更新日期：1983-01-01 00:00:00

abstract：PURPOSE:Capecitabine is an oral chemotherapeutic agent, already used in breast and colon cancer. Previous data showed encouraging results in the treatment of recurrent ovarian cancer. The aim of this study was to describe activity and toxicity of capecitabine in patients with platinum resistant or refractory ovarian ca...

journal_title：Cancer chemotherapy and pharmacology

authors： Pisano C,Morabito A,Sorio R,Breda E,Lauria R,Gebbia V,Scaltriti L,Scalone S,Zagonel V,Greggi S,Beneduce G,Losito S,Gallo C,Di Maio M,Forestieri V,Pignata S

更新日期：2009-10-01 00:00:00

abstract：PURPOSE:Triple-negative breast cancer (TNBC) is an aggressive, lethal, and heterogeneous subtype of breast cancers, tending to have lower 5-year survival rates than other BC subtypes in response to conventional chemotherapies. This study's aim was to identify advanced regimens to effectively control TNBC tumor developm...

journal_title：Cancer chemotherapy and pharmacology

authors： Pattarawat P,Wallace S,Pfisterer B,Odoi A,Wang HR

更新日期：2020-01-01 00:00:00

abstract：PURPOSE:Doxorubicin-based chemotherapy is limited by the development of dose-dependent left ventricular dysfunction and congestive heart failure caused by reactive oxygen species (ROS). Uncoupling proteins (UCP) can inhibit mitochondrial ROS production as well as decrease myocyte damage from exogenous ROS. Prior studie...

journal_title：Cancer chemotherapy and pharmacology

authors： Bugger H,Guzman C,Zechner C,Palmeri M,Russell KS,Russell RR 3rd

更新日期：2011-06-01 00:00:00

abstract：:Fifty-one patients with non-small cell lung cancer (NSCLC) were treated, during a phase II trial, with 4'demethylepipodophyllotoxin-beta-D-ethylidene glucoside (VP16-213). Forty-nine were evaluable for response, and of these two (4%) had partial responses lasting 5 and 6 months. Prior treatment with chemotherapy may h...

journal_title：Cancer chemotherapy and pharmacology

authors： Chapman R,Itri L,Gralla R,Kelsen D,Casper E,Golbey R

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:Low-dose methotrexate (MTX) therapy is the cornerstone treatment of acute lymphoblastic leukemia (ALL) and may enhance the activation of 6-mercaptopurine (6-MP) to 6-thioguanine nucleotides (6-TGN). Yet, data have established that high-dose MTX (HDMTX) hampers the accumulation of 6-TGN in red blood cells (RBC) ...

journal_title：Cancer chemotherapy and pharmacology

authors： Adam de Beaumais T,Dervieux T,Fakhoury M,Medard Y,Azougagh S,Zhang D,Yakouben K,Jacqz-Aigrain E

更新日期：2010-09-01 00:00:00

abstract：PURPOSE:PF-00337210 is an oral, highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor. We evaluated a composite of biomarkers in real time to identify the recommended phase 2 dose (RP2D) and preliminary anticancer activity of PF-00337210. PATIENTS AND METHODS:Patients (Pts) with advanced cance...

journal_title：Cancer chemotherapy and pharmacology

authors： Bruce JY,LoRusso PM,Goncalves PH,Heath EI,Sadowski E,Shalinsky DR,Zhang Y,Traynor AM,Breazna A,Ricart AD,Tortorici M,Liu G

更新日期：2016-03-01 00:00:00

abstract：PURPOSE:One of the major problems of cancer chemotherapy is the development of multidrug resistance (MDR) phenotype. Among the numerous mechanisms of MDR, a prominent one is the increased expression of membrane transporter proteins, the action of which leads to decreased intracellular drug concentration and cytotoxicit...

journal_title：Cancer chemotherapy and pharmacology

authors： Dönmez Y,Akhmetova L,İşeri ÖD,Kars MD,Gündüz U

更新日期：2011-04-01 00:00:00

abstract：PURPOSE:miRNAs are implicated in drug resistance of multiple cancers including non-small cell lung cancer (NSCLC), highlighting the potential of miRNAs as chemoresistance regulators in cancer treatment. This study aims to explore the relationship between miR-181c and chemoresistance of NSCLC cells. METHODS:qRT-PCR was...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang H,Hu B,Wang Z,Zhang F,Wei H,Li L

更新日期：2017-11-01 00:00:00

abstract：:We studied serum lipid and lipoprotein changes occurring during chemotherapy in 57 patients with chemosensitive cancers, including 18 malignant lymphomas, 18 breast carcinomas, 14 small-cell lung carcinomas, and 7 urothelial-cell carcinomas. Patients who responded favorably to chemotherapy demonstrated a significant i...

journal_title：Cancer chemotherapy and pharmacology

authors： Alexopoulos CG,Pournaras S,Vaslamatzis M,Avgerinos A,Raptis S

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:Recently, it was shown that chrysin causes upregulation of UGT1A1 in Caco-2 intestinal cells. Therefore, we proposed that oral chrysin may reduce irinotecan (CPT-11) induced diarrhoea by shifting the SN-38G/SN-38 equilibrium towards the inactive SN-38G in the gastrointestinal mucosa. The purpose of this study w...

journal_title：Cancer chemotherapy and pharmacology

authors： Tobin PJ,Beale P,Noney L,Liddell S,Rivory LP,Clarke S

更新日期：2006-02-01 00:00:00

abstract：PURPOSE:This study aimed to evaluate the maximum tolerated dose (MTD) and recommended phase II dose (RPTD), as well as the safety and tolerability of PF-03446962, a monoclonal antibody targeting activin receptor like kinase 1 (ALK-1), in combination with regorafenib in patients with refractory metastatic colorectal can...

journal_title：Cancer chemotherapy and pharmacology

authors： Clarke JM,Blobe GC,Strickler JH,Uronis HE,Zafar SY,Morse M,Dropkin E,Howard L,O'Neill M,Rushing CN,Niedzwiecki D,Watson H,Bolch E,Arrowood C,Liu Y,Nixon AB,Hurwitz HI

更新日期：2019-10-01 00:00:00

abstract：:Brain microdialysis was applied to sample free methotrexate (MTX) concentrations in brain extracellular fluid of normal and RG-2 glioma-bearing rats. All animals received 50 mg/kg of MTX intra-arterially following which serial blood and interstitial fluid samples were collected for 3 h and measured for MTX by an HPLC ...

journal_title：Cancer chemotherapy and pharmacology

authors： Devineni D,Klein-Szanto A,Gallo JM

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:To investigate the safety of intravenous topotecan monotherapy for relapsed small cell lung cancer (SCLC) patients with pre-existing interstitial lung disease (ILD). METHODS:A total of 77 patients who received topotecan for the treatment of relapsed SCLC between April 2007 and April 2014 were reviewed. Patient...

journal_title：Cancer chemotherapy and pharmacology

authors： Enomoto Y,Inui N,Imokawa S,Karayama M,Hasegawa H,Ozawa Y,Matsui T,Yokomura K,Suda T

更新日期：2015-09-01 00:00:00

abstract：PURPOSE:Previous studies have shown that angiotensin peptides stimulate the proliferation of hematopoietic progenitors in vitro, promote survival after exposure to lethal irradiation as well as accelerate the recovery of white blood cells (WBC), i.e., lymphocytes, monocytes and neutrophils, and platelets. These changes...

journal_title：Cancer chemotherapy and pharmacology

authors： Rodgers K,Xiong S,DiZerega GS

更新日期：2003-02-01 00:00:00

abstract：:In an attempt to establish a relationship between the pharmacokinetics in mouse heart of new anthracycline derivatives and their potential chronic cardiotoxicity and on this way to provide a useful and economical test for screening of new analogs, we followed the accumulation and metabolism of six anthracyclines in th...

journal_title：Cancer chemotherapy and pharmacology

authors： Deprez-de Campeneere D,Baurain R,Trouet A

更新日期：1982-01-01 00:00:00

abstract：:A four-fold (P less than 0.001) mean increase in iron levels was found in 18 patients (a total of 36 courses of therapy) with ovarian cancer at the end of a 5-day course of cisplatin (40 mg/m2 per day every 4-5 weeks). The kinetics of these modifications began very early (24-48 h after initiation of therapy): they rea...

journal_title：Cancer chemotherapy and pharmacology

authors： Pollera CF,Ameglio F,Reina S,Nardi M,Abbolito MR,Parracino C

更新日期：1987-01-01 00:00:00

abstract：:Leucovorin requirements for protection of the T cell line CCRF-CEM and the B cell line LAZ-007 against the cytotoxic effects of a variety of antifolates were studied. Differential leucovorin protection for DDMP-induced growth suppression occurred in the opposite direction to that for MTX, with CCRF-CEM requiring less ...

journal_title：Cancer chemotherapy and pharmacology

authors： Browman GP,Spiegl P,Booker L,Rosowsky A

更新日期：1985-01-01 00:00:00

abstract：PURPOSE:To determine the efficacy and safety of the combination therapy with docetaxel and cisplatin (CDDP) at low doses in elderly patients with advanced NSCLC. PATIENTS AND METHODS:A total of 42 patients aged > or =70 years with previously untreated advanced NSCLC received docetaxel 75 mg/m(2) plus CDDP 50 mg/m(2) o...

journal_title：Cancer chemotherapy and pharmacology

authors： Feliu J,Firvida JL,Castro J,Madroñal C,Rodríguez-Jaráiz A,Salgado M,Belda-Iniesta C,Casado E,García-Mata J,González-Barón M,Oncopaz Cooperative Group.

更新日期：2009-02-01 00:00:00

abstract：PURPOSE:The phosphoinositide-3-kinase (PI3K) pathway is the frequently altered in human cancer. This has led to the development and study of novel PI3K inhibitors for targeted therapy and also to overcome resistance to radiotherapy. METHOD:The anti-tumour effects of PI3K inhibitors (PI-828, PI-103 and PX-866) in terms...

journal_title：Cancer chemotherapy and pharmacology

authors： Aggarwal S,John S,Sapra L,Sharma SC,Das SN

更新日期：2019-03-01 00:00:00

abstract：PURPOSE:To investigate the antitumor effects of tyroserleutide (tyrosyl-seryl-leucine, YSL) on human Bel7402 hepatocarcinoma in vitro and in vivo, with preliminary exploration of its antitumor mechanism. METHODS:MTT was used to observe the anticarcinogenic effects of YSL on human hepatocarcinoma Bel7402 cells in vitro...

journal_title：Cancer chemotherapy and pharmacology

authors： Lu R,Jia J,Bao L,Fu Z,Li G,Wang S,Wang Z,Jin M,Gao W,Yao Z

更新日期：2006-01-01 00:00:00

abstract：:Advanced recurrent squamous cell head and neck cancer patients were prospectively randomized to receive or not receive dibromodulcitol 10 mg/kg PO weekly for 8 consecutive weeks in addition to bleomycin chemotherapy. Patients initially entered in the study received bleomycin 15 mu/m2 three times weekly for 8 weeks. Th...

journal_title：Cancer chemotherapy and pharmacology

authors： Issell BF,Borsos G,D'Aoust JC,Banhidy F,Crooke ST,Eckhardt S

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:Triple-negative breast cancers (TNBCs) do not derive benefit from molecular-targeted treatments such as endocrine therapy or anti-HER2 therapy because they lack those molecular targets. On the other hand, TNBCs have been shown to respond to neoadjuvant chemotherapy (NAC). In this study, we analyzed TNBC patient...

journal_title：Cancer chemotherapy and pharmacology

authors： Masuda H,Masuda N,Kodama Y,Ogawa M,Karita M,Yamamura J,Tsukuda K,Doihara H,Miyoshi S,Mano M,Nakamori S,Tsujinaka T

更新日期：2011-04-01 00:00:00

abstract：:The pharmacokinetics of flavone acetic acid (FAA) after a dose of 4.8 mg/m2 given i.v. over 1 h was investigated in 13 patients with different solid tumors. The mean volume of distribution and clearance were 52 +/- 4 l/m2 and 2.6 +/- 0.2 l/h x m2, respectively. A tumor or metastasis biopsy was obtained from six patien...

journal_title：Cancer chemotherapy and pharmacology

authors： Damia G,Freschi A,Sorio R,Braida A,Caruso G,Quaia M,Monfardini S,D'Incalci M

更新日期：1990-01-01 00:00:00